Cancer Research Versailles No Abst Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcelli, M.
Right arrow Articles by Lamb, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcelli, M.
Right arrow Articles by Lamb, D. J.
[Cancer Research 60, 944-949, February 15, 2000]
© 2000 American Association for Cancer Research

Endocrinology

Androgen Receptor Mutations in Prostate Cancer1

Marco Marcelli2, Michael Ittmann, Stefania Mariani, Richard Sutherland, Rajni Nigam, Lata Murthy, Yali Zhao, Dino DiConcini, Efisio Puxeddu, Adel Esen, James Eastham, Nancy L. Weigel and Dolores J. Lamb

Departments of Medicine [M. M., R. N., E. P.], Molecular and Cellular Biology [M. M., N. L. W., D. J. L.], and Pathology [M. I.], Scott Department of Urology [S. M., R. S., L. M., Y. Z., D. D., A. E., J. E., D. J. L.], Baylor College of Medicine, and Veterans Affairs Medical Center [M. M., M. I.], Houston, Texas 77030

We analyzed the frequency and relevance of mutations in the coding region of the androgen receptor (AR) in genomic DNA extracted from 137 specimens of prostate cancer. The specimens were obtained from the primary tumors of patients affected by stage B disease [15 nonmicrodissected (group 1A) and 84 microdissected (group 1B)] and from the metastatic deposits of individuals with stage D1 disease [8 nonmicrodissected (group 2A) and 30 microdissected (group 2B)] who had not undergone androgen ablation therapy. The study was conducted by PCR-single strand conformational polymorphism (SSCP) analysis of exons 2–8 in the four groups and direct sequence analysis of exon 1 in group 1B. As positive and negative controls, we used genomic DNA extracted from genital skin fibroblasts of patients affected by various forms of androgen resistance with known mutations in the AR. To control for genetic instability, PCR-SSCP analysis of exon 2 of the human progesterone receptor was carried out on each specimen.

The overall number of mutations detected was 11 (8%). No mutations were detected in any of the 99 patients with stage B disease. Eleven mutations were detected in exons 2–8 in 8 of the 38 patients with stage D1 disease (all in group 2B). Simultaneous analysis of exon 2 of the progesterone receptor was carried out, and no SSCP changes were identified.

These data suggest that AR mutations are rare and presumably do not play a role in the initial phase of prostatic carcinogenesis. The presence of a significant number of AR mutations in metastatic disease indicates that mutations of this molecule may play a role in the most advanced phases of the natural history of this disease, either by facilitating growth or acquisition of the metastatic phenotype.




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
K. Malinowska, H. Neuwirt, I. T Cavarretta, J. Bektic, H. Steiner, H. Dietrich, P. L Moser, D. Fuchs, A. Hobisch, and Z. Culig
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Endocr. Relat. Cancer, March 1, 2009; 16(1): 155 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
O. A. O'Mahony, M. P. Steinkamp, M. A. Albertelli, M. Brogley, H. Rehman, and D. M. Robins
Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer
Mol. Cancer Res., November 1, 2008; 6(11): 1691 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. D. Martinez, R. J. Jasavala, I. Hinkson, L. D. Fitzgerald, J. S. Trimmer, H.-J. Kung, and M. E. Wright
RNA Editing of Androgen Receptor Gene Transcripts in Prostate Cancer Cells
J. Biol. Chem., October 31, 2008; 283(44): 29938 - 29949.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Vasaitis, A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L. K. Gediya, Z. Guo, H.-B. Fang, V. C.O. Njar, and A. M.H. Brodie
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3{beta}-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
Mol. Cancer Ther., August 1, 2008; 7(8): 2348 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
C.-L. Hsieh, C. Cai, A. Giwa, A. Bivins, S.-Y. Chen, D. Sabry, K. Govardhan, and L. Shemshedini
Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells
J. Mol. Endocrinol., July 1, 2008; 41(1): 13 - 23.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. J. Maitland and A. T. Collins
Prostate Cancer Stem Cells: A New Target for Therapy
J. Clin. Oncol., June 10, 2008; 26(17): 2862 - 2870.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. G.-W. Wong, T. Nitkunan, I. Oinuma, C. Zhou, V. Blanc, R. S. D. Brown, S. R. J. Bott, J. Nariculam, G. Box, P. Munson, et al.
Plexin-B1 mutations in prostate cancer
PNAS, November 27, 2007; 104(48): 19040 - 19045.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Z. Lu, S. E. Wardell, K. L. Burnstein, D. Defranco, P. J. Fuller, V. Giguere, R. B. Hochberg, L. McKay, J.-M. Renoir, N. L. Weigel, et al.
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 782 - 797.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. B. Wetherill, J. K. Hess-Wilson, C. E.S. Comstock, S. A. Shah, C. R. Buncher, L. Sallans, P. A. Limbach, S. Schwemberger, G. F. Babcock, and K. E. Knudsen
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer
Mol. Cancer Ther., December 1, 2006; 5(12): 3181 - 3190.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Berger, D. I. Lin, M. Nieto, E. Sicinska, L. A. Garraway, H. Adams, S. Signoretti, W. C. Hahn, and M. Loda
Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells
Cancer Res., June 1, 2006; 66(11): 5723 - 5728.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson
Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity
J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Zheng, C. Cai, J. Omwancha, S.-Y. Chen, T. Baslan, and L. Shemshedini
SUMO-3 Enhances Androgen Receptor Transcriptional Activity through a Sumoylation-independent Mechanism in Prostate Cancer Cells
J. Biol. Chem., February 17, 2006; 281(7): 4002 - 4012.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Duff and I. J. McEwan
Mutation of Histidine 874 in the Androgen Receptor Ligand-Binding Domain Leads to Promiscuous Ligand Activation and Altered p160 Coactivator Interactions
Mol. Endocrinol., December 1, 2005; 19(12): 2943 - 2954.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, Y. Shimizu, T. Kamoto, and O. Ogawa
Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated Patient
Cancer Res., November 1, 2005; 65(21): 9611 - 9616.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Pajonk, A. van Ophoven, and W. H. McBride
Hyperthermia-Induced Proteasome Inhibition and Loss of Androgen Receptor Expression in Human Prostate Cancer Cells
Cancer Res., June 1, 2005; 65(11): 4836 - 4843.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Pandini, R. Mineo, F. Frasca, C. T. Roberts Jr., M. Marcelli, R. Vigneri, and A. Belfiore
Androgens Up-regulate the Insulin-like Growth Factor-I Receptor in Prostate Cancer Cells
Cancer Res., March 1, 2005; 65(5): 1849 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. P. Larson, Y. Ding, L. S-C. Cheng, C. Lundberg, V. Gagalang, G. Rivas, L. Geller, J. Weitzel, D. MacDonald, J. Archambeau, et al.
Genetic Linkage of Prostate Cancer Risk to the Chromosome 3 Region Bearing FHIT
Cancer Res., February 1, 2005; 65(3): 805 - 814.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. B. Wetherill, N. L. Fisher, A. Staubach, M. Danielsen, R. W. de Vere White, and K. E. Knudsen
Xenoestrogen Action in Prostate Cancer: Pleiotropic Effects Dependent on Androgen Receptor Status
Cancer Res., January 1, 2005; 65(1): 54 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Unni, S. Sun, B. Nan, M. J. McPhaul, B. Cheskis, M. A. Mancini, and M. Marcelli
Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence
Cancer Res., October 1, 2004; 64(19): 7156 - 7168.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Foley, D. Hollywood, and M. Lawler
Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease
Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. N. Papandreou and C. J. Logothetis
Bortezomib as a Potential Treatment for Prostate Cancer
Cancer Res., August 1, 2004; 64(15): 5036 - 5043.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev., April 1, 2004; 25(2): 276 - 308.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. K. Lee and C. Chang
Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4043 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. G. Nelson, A. M. De Marzo, and W. B. Isaacs
Prostate Cancer
N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381.
[Full Text] [PDF]

Home page
 JCOHome page
M.-E. Taplin, B. Rajeshkumar, S. Halabi, C. P. Werner, B. A. Woda, J. Picus, W. Stadler, D. F. Hayes, P. W. Kantoff, N. J. Vogelzang, et al.
Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663
J. Clin. Oncol., July 15, 2003; 21(14): 2673 - 2678.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. de la Taille, M. A. Rubin, M.-W. Chen, F. Vacherot, S. G.-D. de Medina, M. Burchardt, R. Buttyan, and D. Chopin
{beta}-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells
Clin. Cancer Res., May 1, 2003; 9(5): 1801 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L.-N. Song, R. Herrell, S. Byers, S. Shah, E. M. Wilson, and E. P. Gelmann
{beta}-Catenin Binds to the Activation Function 2 Region of the Androgen Receptor and Modulates the Effects of the N-Terminal Domain and TIF2 on Ligand-Dependent Transcription
Mol. Cell. Biol., March 1, 2003; 23(5): 1674 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
D. J. Lamb, E. Puxeddu, N. Malik, D. L. Stenoien, R. Nigam, G. Y. Saleh, M. Mancini, N. L. Weigel, and M. Marcelli
Molecular Analysis of the Androgen Receptor in Ten Prostate Cancer Specimens Obtained Before and After Androgen Ablation
J Androl, March 1, 2003; 24(2): 215 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Santamaria, P. L. Fernandez, X. Farre, P. Benedit, J. Reventos, J. Morote, R. Paciucci, and T. M. Thomson
PTOV-1, a Novel Protein Overexpressed in Prostate Cancer, Shuttles between the Cytoplasm and the Nucleus and Promotes Entry into the S Phase of the Cell Division Cycle
Am. J. Pathol., March 1, 2003; 162(3): 897 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
M.R. Maduro, R. Casella, E. Kim, N. Levy, C. Niederberger, L.I. Lipshultz, and D.J. Lamb
Microsatellite instability and defects in mismatch repair proteins: a new aetiology for Sertoli cell-only syndrome
Mol. Hum. Reprod., February 1, 2003; 9(2): 61 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hara, J.-i. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki, M. Kusaka, and M. Miyamoto
Novel Mutations of Androgen Receptor: A Possible Mechanism of Bicalutamide Withdrawal Syndrome
Cancer Res., January 1, 2003; 63(1): 149 - 153.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Comuzzi, L. Lambrinidis, H. Rogatsch, S. Godoy-Tundidor, N. Knezevic, I. Krhen, Z. Marekovic, G. Bartsch, H. Klocker, A. Hobisch, et al.
The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
Am. J. Pathol., January 1, 2003; 162(1): 233 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. J. James, I. U. Agoulnik, J. M. Harris, G. Buchanan, W. D. Tilley, M. Marcelli, D. J. Lamb, and N. L. Weigel
A Novel Androgen Receptor Mutant, A748T, Exhibits Hormone Concentration-Dependent Defects in Nuclear Accumulation and Activity Despite Normal Hormone-Binding Affinity
Mol. Endocrinol., December 1, 2002; 16(12): 2692 - 2705.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. G. Tepper, D. L. Boucher, P. E. Ryan, A.-H. Ma, L. Xia, L.-F. Lee, T. G. Pretlow, and H.-J. Kung
Characterization of a Novel Androgen Receptor Mutation in a Relapsed CWR22 Prostate Cancer Xenograft and Cell Line
Cancer Res., November 15, 2002; 62(22): 6606 - 6614.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Gelmann
Molecular Biology of the Androgen Receptor
J. Clin. Oncol., July 1, 2002; 20(13): 3001 - 3015.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Dai, R. Shen, M. Sumitomo, R. Stahl, D. Navarro, M. C. Gershengorn, and D. M. Nanus
Synergistic Activation of the Androgen Receptor by Bombesin and Low-Dose Androgen
Clin. Cancer Res., July 1, 2002; 8(7): 2399 - 2405.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Z.-Q. Huang, J. Li, and J. Wong
AR Possesses an Intrinsic Hormone-Independent Transcriptional Activity
Mol. Endocrinol., May 1, 2002; 16(5): 924 - 937.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. V. Krishnan, X.-Y. Zhao, S. Swami, L. Brive, D. M. Peehl, K. R. Ely, and D. Feldman
A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand Specificity: Therapeutic Implications for Androgen-Independent Prostate Cancer
Endocrinology, May 1, 2002; 143(5): 1889 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor (AR) Coregulators: An Overview
Endocr. Rev., April 1, 2002; 23(2): 175 - 200.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C.-Y. Chang and D. P. McDonnell
Evaluation of Ligand-Dependent Changes in AR Structure Using Peptide Probes
Mol. Endocrinol., April 1, 2002; 16(4): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-B. Shi, A.-H. Ma, L. Xia, H.-J. Kung, and R. W. de Vere White
Functional Analysis of 44 Mutant Androgen Receptors from Human Prostate Cancer
Cancer Res., March 1, 2002; 62(5): 1496 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-Y. Chang, P. J. Walther, and D. P. McDonnell
Glucocorticoids Manifest Androgenic Activity in a Cell Line Derived from a Metastatic Prostate Cancer
Cancer Res., December 1, 2001; 61(24): 8712 - 8717.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
V. Nwosu, J. Carpten, J. M. Trent, and R. Sheridan
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease
Hum. Mol. Genet., October 1, 2001; 10(20): 2313 - 2318.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Buchanan, N. M. Greenberg, H. I. Scher, J. M. Harris, V. R. Marshall, and W. D. Tilley
Collocation of Androgen Receptor Gene Mutations in Prostate Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1273 - 1281.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. F. Shariat, S. Desai, W. Song, T. Khan, J. Zhao, C. Nguyen, B. A. Foster, N. Greenberg, D. M. Spencer, and K. M. Slawin
Adenovirus-mediated Transfer of Inducible Caspases: A Novel "Death Switch" Gene Therapeutic Approach to Prostate Cancer
Cancer Res., March 1, 2001; 61(6): 2562 - 2571.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
B. Lin, J. T. White, C. Ferguson, S. Wang, R. Vessella, R. Bumgarner, L. D. True, L. Hood, and P. S. Nelson
Prostate Short-Chain Dehydrogenase Reductase 1 (PSDR1): A New Member of the Short-Chain Steroid Dehydrogenase/Reductase Family Highly Expressed in Normal and Neoplastic Prostate Epithelium
Cancer Res., February 1, 2001; 61(4): 1611 - 1618.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
F. Yeung, X. Li, J. Ellett, J. Trapman, C. Kao, and L. W. K. Chung
Regions of Prostate-specific Antigen (PSA) Promoter Confer Androgen-independent Expression of PSA in Prostate Cancer Cells
J. Biol. Chem., December 22, 2000; 275(52): 40846 - 40855.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. E. Chipuk, S. C. Cornelius, N. J. Pultz, J. S. Jorgensen, M. J. Bonham, S.-J. Kim, and D. Danielpour
The Androgen Receptor Represses Transforming Growth Factor-beta Signaling through Interaction with Smad3
J. Biol. Chem., January 4, 2002; 277(2): 1240 - 1248.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.